Fate Therapeutics Inc (FATE) - Total Liabilities

Latest as of September 2025: $109.61 Million USD

Based on the latest financial reports, Fate Therapeutics Inc (FATE) has total liabilities worth $109.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Fate Therapeutics Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how Fate Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Fate Therapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Fate Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Fate Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
PT Indonesia Kendaraan Terminal Tbk JK:IPCC	Indonesia	Rp684.41 Billion
VYTRUS BIOTECH EO -01 F:V5P	Germany	€4.35 Million
Coraza Integrated Technology Bhd KLSE:0240	Malaysia	RM83.55 Million
GAMSUNG Corporation Co. Ltd KQ:036620	Korea	₩51.63 Billion
Penta Teknoloji Urunleri Dagitim Ticaret AS IS:PENTA	Turkey	TL8.70 Billion
China New Higher Education Group Limited F:8CN	Germany	€5.81 Billion
Lara Exploration Ltd. V:LRA	Canada	CA$266.12K
Thailand Prime Property Freehold and Leasehold Real Estate Investment Trust BK:TPRIME	Thailand	฿2.70 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down Fate Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Fate Therapeutics Inc (FATE) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.47	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Fate Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Fate Therapeutics Inc (2011–2024)

The table below shows the annual total liabilities of Fate Therapeutics Inc from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	$121.97 Million	-11.49%
2023-12-31	$137.80 Million	-37.82%
2022-12-31	$221.62 Million	-8.65%
2021-12-31	$242.62 Million	+1.93%
2020-12-31	$238.01 Million	+313.80%
2019-12-31	$57.52 Million	+9.43%
2018-12-31	$52.56 Million	+87.04%
2017-12-31	$28.10 Million	+28.36%
2016-12-31	$21.89 Million	-26.82%
2015-12-31	$29.92 Million	+30.86%
2014-12-31	$22.86 Million	+382.87%
2013-12-31	$4.74 Million	-92.59%
2012-12-31	$63.90 Million	+9.17%
2011-12-31	$58.53 Million	--

About Fate Therapeutics Inc

NASDAQ:FATE USA Biotechnology

Market Cap

$241.09 Million

Market Cap Rank

#18239 Global

#4199 in USA

Share Price

$2.09

Change (1 day)

+6.63%

52-Week Range

$0.92 - $2.84

All Time High

$117.40